Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;29(2):125-133.
doi: 10.1002/pds.4903. Epub 2019 Nov 15.

Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials

Tessa A Hulshof  1 , Sytse U Zuidema  1 , Christine C Gispen-de Wied  2 , Hendrika J Luijendijk  1
Affiliations
Review

Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials

Tessa A Hulshof et al. Pharmacoepidemiol Drug Saf. 2020 Feb.

Abstract

Purpose: Run-in periods are used to identify placebo-responders and washout. Our aim was to assess the association of run-in periods with clinical outcomes of antipsychotics in dementia.

Methods: We searched randomized placebo-controlled trials of conventional and atypical antipsychotics for neuropsychiatric symptoms (NPS) in dementia in electronic sources and references of selected articles. We extracted (a) the presence of a run-in period, use of placebo/investigated drug during run-in (versus washout only), and run-in duration (1 week or more) and (b) the reduction in NPS, number of participants with somnolence, extrapyramidal symptoms (EPS), and deaths per treatment group. We pooled clinical outcomes comparing antipsychotic and placebo groups in trials with and without run-in.

Results: We identified 35 trials. Twenty-nine trials used run-in. The pooled standardized mean difference in the reduction of NPS was -0.170 (95% CI, -0.227 to -0.112) in trials with run-in and -0.142 (95% CI, -0.331 to 0.047) in trials without run-in. The pooled odds ratio for somnolence was 2.8 (95% CI, 2.3-3.5) in trials with run-in and 3.5 (95% CI, 1.2-10.7) in trials without run-in; for EPS, these ORs were 1.8 (95% CI, 1.4-2.2) and 2.0 (95% CI, 1.3-3.1) respectively, and for mortality 1.4 (95% CI, 1.0-2.0) and 1.6 (95% CI, 0.7-3.4). The use of placebo/investigated drug during run-in and run-in duration did not affect the estimates in a consistent way.

Conclusions: The use of run-in in trials might have led to overestimated efficacy and especially underestimated risks of side effects of antipsychotics compared with placebo for NPS in dementia.

Keywords: antipsychotics; dementia; efficacy; meta-analysis; pharmacoepidemiology; run-in; side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of literature search and study selection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rothwell P. External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet. 2005;365(1):82‐93. - PubMed
    1. Leber P, Davis C. Threats to the validity of clinical trials sample selection. Control Clin Trials. 1998;19(2):178‐187. - PubMed
    1. Pablos‐Méndez A, Barr R, Shea S. Run‐in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279(3):222‐225. - PubMed
    1. Cipriani A, Gedds J. What is a run‐in phase? Epidemiol Psichiatr Soc. 2010;19(1):21‐22. - PubMed
    1. Ulmer M, Robinaugh D, Friedberg J, Lipsitz S, Natarajan S. Usefulness of a run‐in period to reduce drop‐outs in a randomized controlled trial of a behavioral intervention. Contemp Clin Trials. 2008;29(5):705‐710. - PubMed

MeSH terms

Substances